RVD Induction Therapy in Newly Diagnosed Multiple Myeloma RVD Induction Therapy in Newly Diagnosed Multiple Myeloma
What benefits might be achieved with a combination lenalidomide, bortezomib, and dexamethasone induction regimen in patients with multiple myeloma?Journal of Clinical Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 17, 2020 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

FDA Approves New Drug for Diffuse Large B-Cell Lymphoma FDA Approves New Drug for Diffuse Large B-Cell Lymphoma
A novel drug that targets CD19 has been approved for use with lenalidomide for patients with relapsed or refractory diffuse large B-cell lymphoma.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - August 3, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

NHS England spends £160m on new 'Covid-friendly' cancer drugs
Patients to be given treatments less likely to damage immune system and in some cases able to be taken at homeNHS England is spending £160m on new “Covid-friendly” cancer drugs that will be less likely to damage the immune system and, in some cases, can be taken at home so that patients do not have to visit hospital.NHS England said 2,000 patients had already benefitted from a range of treatments approved for use as “swaps” for existing drugs. More will be available from this week, after a series of deals struck between the NHS and pharma companies, it said in a statement.Some of these new opt...
Source: Guardian Unlimited Science - August 3, 2020 Category: Science Authors: Sarah Boseley Health editor Tags: NHS Cancer Society Health Cancer research Medical research Science UK news Coronavirus outbreak Source Type: news

FDA Approves Monjuvi (tafasitamab-cxix) in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
PLANEGG/MUNICH, Germany - August 1, 2020 and WILMINGTON, Del. - July 31, 2020 MorphoSys AG NASDAQ:MOR) and Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Monjuvi (tafasitamab-cxix) in combination... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - August 1, 2020 Category: Drugs & Pharmacology Source Type: news

Natco Pharma's Canadian unit signs pact with Celgene for cancer treatment drug
Natco Pharma entered into an agreement with biopharmaceutical firm Celgene for Lenalidomide capsules, which is used to treat various types of cancers. It works by slowing or stopping the growth of cancer cells. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - July 10, 2020 Category: Pharmaceuticals Source Type: news

Subcutaneous Daratumumab Combination Resulted in Deep and Rapid Hematologic Responses and Improved Clinical Outcomes in the Treatment of Patients with Newly Diagnosed Light Chain (AL) Amyloidosis
RARITAN, NJ, June 13, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the first randomized Phase 3 study investigating subcutaneous daratumumab[i] in the treatment of patients with newly diagnosed light chain (AL) amyloidosis, a rare and potentially fatal disease.[1],[2] The data demonstrated subcutaneous daratumumab in combination with cyclophosphamide, bortezomib, and dexamethasone (D-CyBorD) resulted in a higher hematologic complete response rate (CR), (53 percent vs. 18 percent [P
Source: Johnson and Johnson - June 15, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Parameswaran Hari, MD, MRCP, Discusses Lenalidomide Maintenance Outcomes in Multiple Myeloma
Parameswaran Hari, MD, MRCP, discussed the progression-free survival of patients who stopped versus continued lenalidomide maintenance therapy to treat multiple myeloma from a follow-up trial presented at the 2020 ASCO Virtual Scientific Program. (Source: CancerNetwork)
Source: CancerNetwork - June 5, 2020 Category: Cancer & Oncology Authors: Parameswaran Hari, MD, MRCP Source Type: news

Carfilzomib Triplet Therapy Shows Inferior PFS in Newly Diagnosed Multiple Myeloma
Carfilzomib combined with lenalidomide and dexamethasone failed to improve progression-free survival, compared with the current standard of care triplet of bortezomib, lenalidomide, and dexamethasone, in patients with newly diagnosed multiple myeloma. (Source: CancerNetwork)
Source: CancerNetwork - May 29, 2020 Category: Cancer & Oncology Authors: Jessica Skarzynski Source Type: news

Carfilzomib does not improve outcomes in newly diagnosed myeloma compared to bortezomib
(ECOG-ACRIN Cancer Research Group) The combination of carfilzomib, lenalidomide, and dexamethasone (KRd) did not improve progression-free survival in patients with newly diagnosed myeloma absent a high-risk disease prognosis, compared with the standard of care -- bortezomib, lenalidomide, and dexamethasone (VRd). The data from a planned interim analysis for the ENDURANCE (E1A11) randomized phase three trial will be presented at the ASCO 2020 plenary. KRd had more severe cardiac, pulmonary, and renal toxicities. Neuropathy was more common among those receiving VRd. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 28, 2020 Category: International Medicine & Public Health Source Type: news

FDA Approves New Therapy for Patients with Previously Treated Multiple Myeloma
FDA approved Sarclisa (isatuximab-irfc), in combination with pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 2, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA Approves Isatuximab Combination for Previously Treated Multiple Myeloma
The FDA approved isatuximab-irfc, in combination with pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least 2 prior therapies, including lenalidomide and a proteasome inhibitor. (Source: CancerNetwork)
Source: CancerNetwork - March 2, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

FDA Grants Priority Review to Tafasitamab/Lenalidomide Combination for DLBCL
The FDA granted priority review to a biologics license application for tafasitamab in combination with lenalidomide for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - March 2, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

Hundreds of lymphoma patients are set to benefit from the first chemotherapy-free treatment
Drugs watchdog NICE today approves NHS use of cutting-edge drug lenalidomide, which will benefit an estimated 900 cancer patients in England. (Source: the Mail online | Health)
Source: the Mail online | Health - February 27, 2020 Category: Consumer Health News Source Type: news

Peter Voorhees, MD, Discusses Results from the Ongoing GRIFFIN Study
The study is evaluating daratumumab plus lenalidomide, bortezomib, and dexamethasone in autologous stem cell transplant eligible patients newly diagnosed with multiple myeloma. (Source: CancerNetwork)
Source: CancerNetwork - February 18, 2020 Category: Cancer & Oncology Authors: Peter Voorhees, MD Source Type: news

Janssen Announces Submission to U.S. FDA for New DARZALEX ® (Daratumumab)-Based Combination Regimen for Patients with Relapsed/Refractory Multiple Myeloma
RARITAN, NJ, February 10, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of DARZALEX® (daratumumab) in combination with Kyprolis® (carfilzomib) and dexamethasone (DKd) for relapsed/refractory multiple myeloma. The sBLA is supported by results from the Phase 3 CANDOR study, which compared treatment with DKd to carfilzomib and dexamethasone (Kd) in patients with multiple myeloma who relapsed after one to three prior lines of therapy. “W...
Source: Johnson and Johnson - February 10, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Lenalidomide/Rituximab Combo Improves PFS in Subgroup of Patients with NHL
Treatment with lenalidomide and rituximab improved progression-free survival, compared with placebo in patients ≥70 years old with indolent non-Hodgkin lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - December 9, 2019 Category: Cancer & Oncology Authors: Gina Columbus Source Type: news

Combination Therapy Induces High Response Among Relapsed/Refractory Follicular Lymphoma
The combination use of polatuzumab-vedotin, obinutuzumab, and lenalidomide showed high complete response rates in patients with relapsed/refractory follicular lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - December 8, 2019 Category: Cancer & Oncology Authors: Kristie L. Kahl Source Type: news

Featured Review: Reducing uncertainties in choosing first-line treatment in newly diagnosed multiple myeloma
Multiple myeloma is a type of blood cancer. It accounts for approximately 2% of all cancers and is still considered incurable. For people with newly diagnosed multiple myeloma (NDMM), who are unsuitable for a procedure where damaged blood cells are replaced with healthy ones (stem-cell transplant), treatment is usually a multiple drug combination of bortezomib, lenalidomide, or thalidomide, plus melphalan and prednisolone (MP) or dexamethasone (D). Multiple drug combinations are approved for initial anti-myeloma therapy, however, access to these medicines is restricted in many countries worldwide.The Cochrane Review used n...
Source: Cochrane News and Events - November 26, 2019 Category: Information Technology Authors: Katie Abbotts Source Type: news

Lenalidomide Slows Progression of Smoldering Multiple Myeloma Lenalidomide Slows Progression of Smoldering Multiple Myeloma
Early treatment with lenalidomide significantly delays the progression of smoldering multiple myeloma to symptomatic disease, according to the results of a randomized trial.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - November 23, 2019 Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news

Lenalidomide Delays Progression in Smoldering Multiple Myeloma
THURSDAY, Nov. 7, 2019 -- Lenalidomide significantly delays progression to symptomatic multiple myeloma in patients with smoldering multiple myeloma, according to a study published online Oct. 25 in the Journal of Clinical Oncology. Sagar Lonial,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 7, 2019 Category: Pharmaceuticals Source Type: news

Smoldering Multiple Myeloma Can Be Slowed by Lenalidomide
Early treatment with lenalidomide can stave off multiple myeloma and provide longer progression-free survival (PFS) than just monitoring alone. (Source: CancerNetwork)
Source: CancerNetwork - October 29, 2019 Category: Cancer & Oncology Authors: Seth Augenstein Source Type: news

Lenalidomide may delay onset of myeloma-related bone, organ damage
ROCHESTER Minn. -- The largest randomized trial in asymptomatic patients with smoldering multiple myeloma suggests that lenalidomide, a cancer drug, may delay the onset of bone and other myeloma-related organ damage. Results of the study, which was conducted by the Eastern Cooperative Oncology Group and funded by the National Cancer Institute, were published Friday, Oct. [...] (Source: Mayo Clinic Research News)
Source: Mayo Clinic Research News - October 26, 2019 Category: Research Source Type: news

lenalidomide (Revlimid)
Title: lenalidomide (Revlimid)Category: MedicationsCreated: 3/25/2015 12:00:00 AMLast Editorial Review: 8/22/2019 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - August 22, 2019 Category: Cancer & Oncology Source Type: news

Promising New Combo Found For DLBCL
A combination of ibrutinib, lenalidomide, and rituximab was tested on patients with  relapsed or refractory diffuse large B-cell lymphoma, particularly those with non-GCB subtype. (Source: CancerNetwork)
Source: CancerNetwork - August 7, 2019 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

GALEN Study Examines Lenalidomide, Obinutuzumab Combo in Follicular Lymphoma
In this phase II GALEN study, researchers examined the effects of lenalidomide and obinutuzumab in patients with relapsed or refractory follicular lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - July 16, 2019 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

FDA Approves Daratumumab Combination For Multiple Myeloma
The FDA approved daratumumab in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. (Source: CancerNetwork)
Source: CancerNetwork - June 28, 2019 Category: Cancer & Oncology Authors: Erin Kayata Source Type: news

Janssen Announces U.S. FDA Approval of DARZALEX ® (daratumumab) in Combination with Lenalidomide and Dexamethasone for Newly Diagnosed Patients with Multiple Myeloma Who Are Transplant Ineligible
(Source: Johnson and Johnson)
Source: Johnson and Johnson - June 27, 2019 Category: Pharmaceuticals Source Type: news

Janssen Announces FDA Approval of Darzalex (daratumumab) in Combination with Lenalidomide and Dexamethasone for Newly Diagnosed Patients with Multiple Myeloma Who Are Transplant Ineligible
HORSHAM, Pa., June 27, 2019– The Janssen Pharmaceutical Companies of Johnson& Johnson announced today the U.S. Food and Drug Administration (FDA) approval of Darzalex (daratumumab) in combination with lenalidomide and dexamethasone (Rd)... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - June 27, 2019 Category: Drugs & Pharmacology Source Type: news

Could Lenalidomide Be a New Standard for High-Risk Smoldering Myeloma?
Results from a second clinical trial examined the use of lenalidomide treatment in patients with high-risk smoldering multiple myeloma, where the standard of care has been observation. (Source: CancerNetwork)
Source: CancerNetwork - June 6, 2019 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

Lymphoma trial finds combination targeted therapy effective prior to chemotherapy
(University of Texas M. D. Anderson Cancer Center) Results of a Phase II clinical trial conducted at The University of Texas MD Anderson Cancer Center revealed that combination targeted therapy, consisting of rituximab, lenalidomide and ibrutinib (RLI), had an 84.6 percent overall response rate (ORR) and 38.5% complete response rate (CRR) when given prior to any chemotherapy for newly diagnosed patients with a specific type of diffuse large b-cell lymphoma (DLBCL). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 4, 2019 Category: International Medicine & Public Health Source Type: news

Lenalidomide + Rituximab Beneficial in Relapsed/Refractory Non-Hodgkin Lymphoma
The MAGNIFY phase IIIb trial looked at the efficacy and safety of lenalidomide combined with rituximab in  relapsed/refractory indolent non-Hodgkin lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - June 3, 2019 Category: Cancer & Oncology Authors: Jim Kling Source Type: news

Lenalidomide/Anti-CD19 Antibody Combo Yields Encouraging Results in Poor-Prognosis DLBCL
Researchers studied the Fc-enhanced, humanized anti-CD19 antibody MOR208 combined with lenalidomide in  relapsed/refractory large B-cell lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - June 3, 2019 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

Daratumumab Triplet for First-Line Myeloma, but Questions Remain Daratumumab Triplet for First-Line Myeloma, but Questions Remain
The daratumumab, lenalidomide, and dexamethasone triplet is a new frontline option for patients with multiple myeloma who are not candidates for transplant, but how practice-changing are the data?Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 29, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Daratumumab Cuts Risk for Progression in Multiple Myeloma
WEDNESDAY, May 29, 2019 -- For patients with newly diagnosed multiple myeloma, the addition of daratumumab to lenalidomide and dexamethasone is associated with a reduced risk for disease progression or death, according to a study published in the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 29, 2019 Category: Pharmaceuticals Source Type: news

FDA Approves Combo for Indolent Non-Hodgkin Lymphomas FDA Approves Combo for Indolent Non-Hodgkin Lymphomas
Lenalidomide may now be used in combination with rituximab for previously treated follicular lymphoma and previously treated marginal zone lymphoma.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 29, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

FDA approves lenalidomide for follicular and marginal zone lymphoma
Hematology/Oncology News Burs (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - May 29, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Lenalidomide Approved by FDA for Follicular and Marginal Zone Lymphoma
This thalidomide analogue is also indicated for multiple myeloma and myelodysplastic syndromes. (Source: CancerNetwork)
Source: CancerNetwork - May 28, 2019 Category: Cancer & Oncology Authors: Drew Boxler Source Type: news

FDA Approves Revlimid (lenalidomide) In Combination with Rituximab for the Treatment of Adult Patients with Previously Treated Follicular Lymphoma or Marginal Zone Lymphoma
SUMMIT, N.J.--(BUSINESS WIRE) May 28, 2019 -- Celgene Corporation (NASDAQ: CELG) today announced the U.S. Food and Drug Administration (FDA) approved Revlimid (lenalidomide) in combination with a rituximab product (R²) for the treatment of... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 28, 2019 Category: Drugs & Pharmacology Source Type: news

Lenalidomide Delays Onset of Multiple Myeloma Lenalidomide Delays Onset of Multiple Myeloma
In patients with both high-risk and intermediate smoldering myeloma, treatment with single-agent lenalidomide significantly delayed progression to full-blown disease.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 20, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Multiple myeloma: DNA rearrangement may predict poor outcomes
(Emory Health Sciences) In multiple myeloma, Ig lambda translocations may indicate poor outcomes and resistance to immunomodulatory drugs such as lenalidomide. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 23, 2019 Category: Cancer & Oncology Source Type: news

Lenalidomide Plus Rituximab Ups Response in Relapsed Indolent Lymphoma Lenalidomide Plus Rituximab Ups Response in Relapsed Indolent Lymphoma
In patients with relapsed or refractory indolent non-Hodgkin lymphoma, adding lenalidomide to rituximab improves response, according to a placebo-controlled trial.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - April 4, 2019 Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news

Moffitt CEO to be inducted into the 2019 Florida Inventors Hall of Fame
President and CEO of  Moffitt Cancer Center, Dr. Alan List, is being inducted into the 2019 Florida Inventors Hall of Fame for developing new therapeutic strategies for treating blood cancers. Internationally recognized for his contributions in the development of more effective treatment strategies for myelodysplasti c syndrome and acute myeloid leukemia, List's work led to the development of lenalidomide, which received approval from the U.S. Food and Drug Administration. The treatment transformed… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - March 27, 2019 Category: Pharmaceuticals Authors: Kelsey Sunderland Source Type: news

Big Jump in PFS With Combo for Indolent NHL
(MedPage Today) -- Lenalidomide-rituximab more than doubles PFS in relapsed/refractory disease (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - March 26, 2019 Category: Hematology Source Type: news

U.S. court rejects Alvogen's patent challenge for Celgene's cancer drug
The U.S. patent office on Thursday rejected a filing by Alvogen Pine Brook Llc for a review challenging patents on Celgene Corp's blockbuster myeloma drug Revlimid. (Source: Reuters: Health)
Source: Reuters: Health - March 14, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Drug Combo Granted Priority Review for Untreated Follicular Lymphoma
The FDA has granted Priority Review to Celgene ’s application for lenalidomide in combination with rituximab for previously untreated follicular lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - March 12, 2019 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

Lenalidomide Maintenance vs Observation For Newly Diagnosed Myeloma
Can lenalidomide maintenance significantly improve progression-free survival in patients with newly diagnosed myeloma? (Source: CancerNetwork)
Source: CancerNetwork - February 18, 2019 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

MRD Status a Superior Predictor of PFS in Multiple Myeloma?
The study also looked at how lenalidomide maintenance further increases the rate of negative MRD results in multiple myeloma patients. (Source: CancerNetwork)
Source: CancerNetwork - January 24, 2019 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

Addressing uncertainty in cost-effectiveness case for lenalidomide
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - January 1, 2019 Category: Drugs & Pharmacology Source Type: news

Lenalidomide cost effective in newly diagnosed multiple myeloma
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - January 1, 2019 Category: Drugs & Pharmacology Source Type: news